Meeting
2024 ASCO Breakthrough
Preliminary analysis of PD-1 inhibitors combined with chemotherapy as neoadjuvant therapy for local advanced non-small cell lung cancer (NSCLC).
Authors
Hongru Li
Fujian Provincial Hospital, Fuzhou, Fujian, China
Hongru Li , Xiao jie Yang , Tianxing Guo , Jiabin Fang , Nengluan Xu , Sufang Chen , Qiongyao Zhang , Ying Lin , Xiaojie Pan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Advanced Disease
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 200)
DOI
10.1200/JCO.2024.42.23_suppl.200
Abstract #
200
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).
First Author: Zerui Zhao
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
First Author: Xin-Gang Bi